Acknowledgments
The author thanks CONICET and University of La Plata, where he
holds permanent positions.References
- Klabunde T, Everts A (2005) GPCR antitarget
modeling: pharmacophore models for biogenic
amine binding GPCRs to avoid GPCR-
mediated side effects. Chembiochem
6:876–889 - Raschi E, Vasina V, Poluzzi E, De Ponti F
(2008) The hERG Kþchannel: target and
antitarget strategies in drug development.
Pharmacol Res 57:181–195 - Crivori P (2008) Computational models for
P-glycoprotein substrates and inhibitors. In:
Vaz RJ, Klabunde T (eds) Anti-targets: predic-
tion and prevention of drug side effects. Wiley-
VCH, Weinheim - Zamora I (2008) Site of metabolism predic-
tions: facts and experiences. In: Vaz RJ, Kla-
bunde T (eds) Anti-targets: prediction and
prevention of drug side effects. Wiley-VCH,
Weinheim - Hartenfeller M, Schneider G (2011) De novo
drug design. Methods Mol Biol 672:299–323 - Nicolaou CA, Brown N (2013) Multi-
objective optimization methods in drug
design. Drug Discov Today Technol 10:e427-
e435 - Talevi A (2016) Tailored multi-target agents.
Applications and design considerations. Curr
Pharm Des 22:3164–3170 - Lipinski CA, Lombardo F, Dominy BW, Fee-
ney PJ (1997) Experimental and computa-
tional approaches to estimate solubility and
permeability in drug discovery and develop-
ment settings. Adv Drug Deliv Rev 23:3–25 - Pajouhesh H, Lenz GR (2005) Medicinal
chemical properties of successful central ner-
vous system drugs. NeuroRx 2:542–553 - Gupta S, Kesarla R, Omri A (2013) Formula-
tion strategies to improve the bioavailability of
poorly absorbed drugs with special emphasis
on self-emulsifying systems. ISRN Pharm
2013(848043) - Miller DC, Klute W, Calabrese A, Brown AD
(2009) Optimising metabolic stability in lipo-
philic chemical space: the identification of a
metabolic stable pyrazolopyrimidine CRF-1
receptor antagonist. Bioorg Med Chem Lett
19:6144–6147 - Wager TT, Hou X, Verhoest PR, Villalobos A
(2010) Moving beyond rules: the development
of a central nervous system multiparameter
optimization (CNS MPO) approach to enable
alignment of druglike properties. ACS Chem
Neurosci 1:435–449 - He X (2009) Integration of physical, chemical,
mechanical and biopharmaceutical properties
in solid dosage oral form development. In:
Qiu Y, Chen Y, Zhang GGZ, Liu L, Porter
WR (eds) Developing solid dosage oral forms:
pharmaceutical theory and practice, 1st edn.
Academic press, Burlington - Gashaw I, Ellinghaus P, Sommer A, Asadullah
K (2011) What makes a good drug target.
Drug Discov Today 16:1037–1043 - Knowles J, Gromo G (2003) Target selection in
drug discovery. Nat Rev Drug Discov 2:63–69 - Schmidtke P, Barril X (2010) Understanding
and predicting druggability. A high-
throughput method for detection of drug
binding sites. J Med Chem 53:5858–5867 - Yuan Y, Pei J, Lai L (2013) Binding site detec-
tion and druggability prediction of protein tar-
gets for structure-based drug design. Curr
Pharm Des 19:2326–2333 - Barril X (2013) Druggability predictions:
methods, limitations and applications. WIREs
Comput Mol Sci 3:327–338 - Smith RB (2011) Repositioned drugs: inte-
grating intellectual property and regulatory
strategies. Drug Discov Today Ther Strateg
8:131–137 - Novac N (2013) Challenges and opportunities
of drug repositioning. Trends Pharmacol Sci
34:267–272 - Szymanski P, Markowicz M, Mikiciuk-Olasik E
(2012) Adaptation of high-throughput screen-
ing in drug discovery - toxicological screening.
Int J Mol Sci 13:427–452 - Harris CJ, Hill RD, Sheppard DW, Slater MJ,
Stouten PF (2011) The design and application
of target-focused compound libraries. Comb
Chem High Throughput Screen 14:521–531 - Welsch ME, Snyder SA, Stockwell BR (2010)
Privileged scaffolds for library design and drug
discovery. Curr Opin Chem Biol 14:347–361
Computer-Aided Drug Design 17